This fall Outcomes 2022: Extra firms introduced their January-March quarter outcomes on Thursday. The businesses which declared their quarterly outcomes included Exide Industries Restricted, Borosil Renewables and Morepen Laboratories. Listed here are key highlights of the earnings reported by these firms.
Exide This fall Outcomes 2022: Battery firm studies web revenue of Rs 3,953 cr in This fall
Battery producer Exide Industries on Thursday reported a consolidated web revenue of Rs 3,953 crore for the fourth quarter ended March 2022.
The corporate had posted a web revenue of Rs 320 crore within the January-March quarter of 2020-21 fiscal.
The battery maker accomplished the sale of its unit — Exide Life Insurance coverage Firm Ltd on January 1, 2022, leading to a acquire of Rs 4,694 crore.
Income from operations rose to Rs 3,523 crore within the fourth quarter as towards Rs 3,024 crore within the year-ago interval, Exide Industries mentioned in a regulatory submitting.
For the yr ended March 31, 2022, the corporate posted a consolidated web revenue of Rs 4,357 crore. It was Rs 803 crore in FY 2021.
Income from operations stood at Rs 12,789 crore within the final monetary yr, as towards Rs 10,359 crore in 2020-21.
“The corporate was profitable in appreciably reducing mounted prices; nevertheless, this might not totally neutralise the inflationary impression of sharp and continued escalation in costs of inputs, coupled with runaway gasoline and freight prices, resulting in a decline in working margins,” Exide Industries MD & CEO Subir Chakraborty mentioned.
Decreasing of mounted prices happened from the daring initiatives undertaken in gross sales transformation and price compression methods, that are presently yielding good-looking outcomes, he added.
Underneath the newly shaped wholly-owned subsidiary, Exide Vitality Options, the corporate plans to set-up a multi-gigawatt hour lithium-ion cell manufacturing facility, Chakraborty mentioned.
“Unfold out throughout two common cell chemistries and three cell codecs, this unit shall be uniquely positioned to cater to the varied necessities of consumers in India,” he added.
The corporate mentioned its board has declared an interim dividend of Rs 2 per share on the face worth of Re 1 every for the yr 2021-22.
Exide Industries shares ended at Rs 148 on the NSE on Thursday and had been up per cent from the Wednesday closing worth.
Borosil Renewables This fall Outcomes 2022: web revenue dips to Rs 46.38 cr in March quarter
Borosil Renewables’ March 2022 quarter web revenue fell to Rs 46.38 crore towards Rs 66.87 crore within the year-ago interval, primarily resulting from decrease revenues.
The entire revenue declined to Rs 182.33 crore within the quarter from Rs 196.90 crore a yr in the past, confirmed a regulatory submitting on Thursday.
Its web revenue rose to Rs 165.84 crore in 2021-22 from Rs 89.64 crore in 2020-21. For FY22, the entire revenue elevated to Rs 664.73 crore from Rs 507.63 crore within the previous fiscal.
The corporate is engaged solely within the enterprise of manufacture of flat glass, which is a single phase by way of Indian Accounting Commonplace Working Segments (lnd AS-108).
shares ended at Rs on the NSE on Thursday and had been up per cent from the Wednesday closing worth.
Morepen This fall Outcomes 2022: web drops 55% to Rs 12 cr
Drug agency Morepen Laboratories on Thursday mentioned its consolidated web revenue declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.
The corporate had reported a web revenue of Rs 27 crore within the January-March quarter of 2020-21 fiscal.
Complete revenue elevated to Rs 371 crore for the interval underneath evaluation as towards Rs 291 crore within the fourth quarter of 2020-21 monetary yr, Morepen Laboratories mentioned in a regulatory submitting.
For the yr ended March 31, 2022, the drug agency reported a consolidated web revenue of Rs 102 crore as in comparison with Rs 97 crore in FY 2021.
Complete revenue elevated to Rs 1,557 crore throughout the interval underneath evaluation. It was Rs 1,200 crore within the year-ago interval.
“The corporate has been in a position to develop its market share and grown in all enterprise segments and expects to extend its profitability parameters within the subsequent few quarters as soon as the provision disruptions are normalised, which have resulted in elevated enter prices,” Morepen Laboratories Chairman and Managing Director Sushil Suri famous.
The corporate continues to spend money on creating new markets and launch new merchandise to achieve an increasing number of clients, he added.
He additional mentioned: “We’ve got received shareholder’s approval for the conversion of financial institution’s desire shares into fairness capital, which is underway, whereas we anticipate the regulatory approvals. It is going to be an enormous milestone for the corporate, as soon as the method is accomplished.”
Morepen shares ended at Rs 42.70 on the NSE on Thursday and had been down over 11 per cent from the Wednesday closing worth.
With Inputs from PTI